Catalyst
Slingshot members are tracking this event:
GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GWPH |
|
|
||||
Additional Information
- Orphan Drug Designation Granted from FDA for Epidiolex for the Treatment of IS - - Phase 3 Trial Expected to Commence in Q4 2016 -Epidiolex is already being developed in three other orphan indications within the field of pediatric epilepsy — Dravet syndrome, Lennox-Gastaut syndrome (LGS) and Tuberous Sclerosis Complex (TSC). In March 2016, GW announced positive results from the first Phase 3 trial in Dravet syndrome. Results of the first Phase 3 trial in LGS are expected in June 2016.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 21, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cannabidiol, Cbd, Infantile Spasms, Epidiolex, Cannabinoid, West Syndrome, Dravet Syndrome, Lennox-gastaut Syndrome, Tuberous Sclerosis Complex
